Browser storage is unavailable. Keep this page open and export your collection before leaving.
Adventris makes cancer vaccines. Our platform solves the problem of targeting poorly immunogenic oncogenes. Our first "off-the-shelf" vaccine targets KRAS, the most common cancer oncogene. In the long run, we envision a world where every adult receives our pan-cancer vaccines annually – preventing the majority of cancer deaths. If you are intere
Adventris makes cancer vaccines. Our platform solves the problem of targeting poorly immunogenic oncogenes. Our first "off-the-shelf" vaccine targets KRAS, the most common cancer oncogene. In the long run, we envision a world where every adult receives our pan-cancer vaccines annually – preventing the majority of cancer deaths.
If you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at contact@adventris.com
Previously Elimivax
Jen Herbach is the CEO of Adventris Pharmaceuticals. She has more than a decade of biotech industry experience bringing novel oncology drugs to market, across companies including Onyx/Amgen, InterMune/Genentech, Exelixis, and Amunix. She holds an MBA from Harvard Business School and a Masters from the University of Cambridge.
William Collis is a serial entrepreneur with multiple exits, most recently the data platform Genji. His research has been published in Harvard Business review and featured as a TED talk with over 1.5M views. He holds an MBA from Harvard Business School where he was named a Baker Scholar. He is lifelong friends with his co-founders Jen Herbach and Mark Yarchoan, since meeting as roommates at Amherst College.
Mark Yarchoan, M.D, is an Associate Professor of Medical Oncology at Johns Hopkins. Dr. Yarchoan runs an NCI-funded laboratory focused on developing novel immunotherapies, with a focus on cancer vaccines. He has led multiple international clinical trials of immunotherapy agents including neoantigen-targeted cancer vaccines. Dr. Yarchoan has received multiple honors, including the ASCO Young Investigator Award and the ASCO Career Development Award.
Founded 2022 · Source
Source-based assessment · automated evidence rules
The retained text does not establish product availability or customer use.
Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.
abinitio bio is the AI-native operating platform for drug development and manufacturing.
Founders · Product · How it works
Same category · Biotech pharma
Our autonomous biodefense capabilities ensure validated point-of-care diagnostics for emerging biological threats are developed in days, not 12+ months.
Founders
Same category · Biotech pharma
Anthrogen is engineering post-modality biology. Today's modalities reflect historical contingencies in biological progress, not fundamental categories. We develop the AI systems that design modular biological machines and the…
Founders · Product
Same category · Biotech pharma
Anto is building a foundation model for microbial communities, making the gut microbiome computable for the first time. We predict drug toxicity and efficacy across diverse populations and fix drugs so they work for everyone — solving…
Founders · Product
Same category · Biotech pharma
Generative AI Medical Writing Solution for Biotech, Life Sciences, Pharma & Medical Devices | Artos AI. Book a demo online.
Customers · Founders · Product
Same category · Biotech pharma
Astraea is AI software for clinical trial teams. Build SDTM, ADaM and TFL outputs in your environment, with qualified experts reviewing every output.
Founders · Product · How it works
Same category · Biotech pharma
